Collagen Matrix, Inc. (“Collagen Matrix”), a leading provider of high-quality products and technology used in tissue repair and regeneration, today announced an addition to its management team by naming Bart J. Doedens, former President of Biomet 3i, as its new Chief Executive Officer, effective immediately. Collagen Matrix Founder Dr. Shu-Tung Li has transitioned from the Chief Executive Officer role to Chief Scientific Officer and will remain on the company’s Board of Directors.
“Bart brings a wealth of experience to Collagen Matrix with a diversified background and a proven track record of accelerating top-line growth in the medical device space,” said Dr. Shu-Tung Li. “He is a welcome and valuable addition to Collagen Matrix’s leadership team, and I believe his expertise will be an asset to the future success of the company.”
Before joining Collagen Matrix, Doedens served as President of Biomet 3i, a leading dental implant manufacturer based in Palm Beach Gardens, Florida. Prior to that position, he was a Vice President at Sirona Dental Systems Inc., of Long Island City, New York, where he was responsible for leading the CAD/CAM business unit and business development. Doedens also held executive roles at Atlas Spine Inc., Biomet Inc. and Mallinckrodt Medical, Inc. (currently Covidien), where he led strategic expansion initiatives as well as marketing, sales and R&D efforts. Doedens holds an M.D. from the Free University of Amsterdam and an MBA from the University of Rochester’s executive program at the University of Rotterdam.
“I am thrilled to be joining the talented and accomplished team at Collagen Matrix,” said Bart Doedens. “The company is a clear leader in a number of attractive, high-growth areas. I am excited to work with Dr. Li and the rest of the leadership team to make sure we continue to grow by remaining on the cutting edge of innovation and providing the best possible products.”
About Collagen Matrix
Collagen Matrix is a leader in the design and engineering of collagen- and mineral-based extracellular matrices for tissue and organ repair and regeneration. Since its inception in 1997, the Company has received many government grants for the development of innovative, collagen-based matrix products in the areas of neurological, vascular, urological, and orthopedic tissue regeneration applications. The Company currently manufactures collagen-based finished medical devices in the areas of oral/maxillofacial surgery, neurosurgery, and orthopedic-spine surgery. For more information about the Company, please visit www.collagenmatrix.com.
For more information, please contact:
For Collagen Matrix: Peggy Hansen, 201-405-1477, firstname.lastname@example.org